Broshy Eran's Form 4/A amendment
AmendedTheravance Biopharma, Inc. (TBPH) · filed Nov 14, 2025
- Accession no.
- 0001256230-25-000007
- Filed
- Nov 14, 2025
- Trade date
- Nov 11, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Nov 13, 2025
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $809.3K. It was filed 3 days after the trade.
This amendment replaces 0001256230-25-000006 (filed Nov 13, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Broshy EranCIK 0001256230 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Ordinary Shares | SSaleDisposed | −15,500 | $18.50F1 | −$286,750 | 75,704 | Direct | |
| Nov 11, 2025 | Ordinary Shares | SSaleDisposed | −15,500 | $17.00F1 | −$263,500 | 60,204 | Direct | |
| Nov 11, 2025 | Ordinary Shares | SSaleDisposed | −14,000 | $18.50F2 | −$259,000 | 60,204 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Ordinary Shares | MOption exerciseAcquired | +14,000 | $10.15 | +$142,100 | 107,878 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
Referenced by the price of 2 transactions in Table I.
- F2
The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
Referenced by the price of 1 transaction in Table I.
- F3
This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).
Remarks
This Form 4/A is being filed to correct an administrative error in the number of Ordinary Shares reported as sold at $18.50 on November 11, 2025. The originally reported amount of 29,500 shares in Table I, Row 1 was incorrect; the correct amount is 15,500 shares. The number of Ordinary Shares beneficially owned following the transactions has been correspondingly adjusted in all three rows of Table I.